Point-of-Care Testing-Based Supplementary Parameters for the Early Identification of Reduced Kidney Function in Adults
Research
DOI:
https://doi.org/10.55175/cdk.v53i10.2278Keywords:
Early detection, kidney function, POCT, substitute laboratory parameter, uric acidAbstract
Introduction: Declining kidney function often goes undetected due to limited access to conventional laboratory testing. Pos Pembinaan Terpadu (Posbindu) provides simple point-of-care testing (POCT)–based laboratory examinations that can serve as screening parameters for early detection of kidney function impairment. This study aimed to assess the ability of POCT parameters used in Posbindu to predict decreased kidney function in adults. Methods: A cross-sectional study was conducted in five administrative regions of Jakarta from July 2024 to June 2025, involving participants who met the inclusion criteria. The variables included simple POCT parameters such as blood glucose, hemoglobin, hematocrit, uric acid, and lipid profile. Kidney function was determined using the estimated glomerular filtration rate (eGFR; CKD-EPI) with cutoffs of < 80 mL/min/1.73 m² and < 60 mL/min/1.73 m². Spearman correlation analysis was performed to evaluate initial associations, followed by receiver operating characteristic (ROC) analysis to assess discriminatory ability. Confidence intervals were calculated using the Fieller, Hartley, and Pearson methods. Results: Among the 235 respondents, 99 had an eGFR < 80 mL/min/1.73 m², and 18 had an eGFR < 60 mL/min/1.73 m². ROC analysis revealed variability in the predictive ability of the parameters for both kidney function categories: hemoglobin (area under the curve/AUC 0.494 vs. 0.524), fasting blood glucose (AUC 0.549 vs. 0.601), total cholesterol (AUC 0.562 vs. 0.503), HDL (AUC 0.512 vs. 0.457), and LDL (AUC 0.535 vs. 0.427), all of which were not significant (p > 0.05). The parameters with better predictive ability were uric acid (AUC 0.591, p = 0.017 at eGFR < 80; AUC 0.681, p = 0.011 at eGFR < 60 mL/min/1.73 m2, followed by triglycerides, which showed a significant association only at eGFR < 60 (AUC 0.663, p = 0.021) but not at eGFR < 80 (AUC 0.561, p = 0.109). Uric acid demonstrated the strongest and most consistent discriminatory ability, supported by biological plausibility involving oxidative stress, endothelial dysfunction, and afferent arteriolar changes that accelerate glomerular filtration decline. Triglycerides showed a complementary but more limited role, consistent with lipid-mediated kidney injury that typically becomes more apparent at more advanced stages of function decline. Given the cross-sectional design, we could not establish causal or temporal relationships, including the possibility of reverse causality. Conclusion: Uric acid demonstrated the most consistent discriminatory ability for declining kidney function at both the mild and moderate-to-severe decline thresholds, whereas triglycerides showed significant discriminatory ability only at the moderate-tosevere threshold, supporting the potential of both as substitute POCT-based parameters for the early screening of declining kidney function in the adult population.
Downloads
References
Qin K, Qing J, Wang Q, Li Y. Epidemiological shifts in chronic kidney disease: a 30-year global and regional assessment. BMC Public Health. 2024 Dec 18;24(1):3519. doi: 10.1186/s12889-024-21065-9.
Wang H, Bai Z, Shen C, Kou J, Zhu Y, Xie H, et al. The global, regional, and national patterns of change in the burden of bacterial pyoderma from 1990 to 2019 and the forecast for the next decade. Sci Rep. 2025 Jan 13;15(1):1810. doi: 10.1038/s41598-025-85995-z.
Hidayangsih PS, Tjandrarini DH, Sukoco NEW, Sitorus N, Dharmayanti I, Ahmadi F. Chronic kidney disease in Indonesia: evidence from a national health survey. Osong Public Heal Res Perspect. 2023 Feb 28;14(1):23–30. doi: 10.24171/j.phrp.2022.0290.
Astuti T, Wibowo SA. Bridging the gap of information source and access to dialysis services with klikdialisis.com, as an integrated digital communication platform. Malahayati Nurs J. 2022 Nov 1;4(11):3090–107. doi: 10.33024/mnj.v4i11.7268.
Hyodo T, Hirawa N, Kuragano T, Takemoto Y, Urabe S, Adiya S, et al. The present status of dialysis patients in Asian countries as of 2022 from a medical economic point of view. Ren Replace Ther. 2025 Jan 6;11:3. doi: 10.1186/s41100-024-00597-1.
Kementerian Kesehatan Republik Indonesia. PNPK 2023: tata laksana penyakit ginjal kronik [Internet]. Jakarta: Kementerian Kesehatan Republik Indonesia; 2023. Available from: https://www.kemkes.go.id/id/pnpk-2023---tata-laksana-penyakit-ginjal-kronik.
Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan 1;3(1):1–150. doi: 10.1038/KISUP.2012.73.
Yonata A, Taruna A, Islamy N. Deteksi dini dan pencegahan penyakit ginjal. Jurnal Pengabdian Masyarakat Ruwa Jurai 2020;5(1):62-6. https://doi.org/10.23960/jpmrj.v5i1.2806.
Rahman Z, Atrie UY, Ernawati E. Edukasi upaya pencegahan gagal ginjal kronis pada pasien hipertensi dan diabetes melitus. J Salingka Abdimas. 2024 Dec 20;4(2):188–92. doi: 10.31869/jsam.v4i2.5986.
Drew C, Santoso AH, Gunaidi FC, Zhalila Z, Pranata CC. Upaya menjaga kesehatan ginjal dengan pemeriksaan eGFR dan serum kreatinin sejak awal pada populasi usia produktif di Kelurahan Grogol. Nusant J Pengabdi Kpd Masy. 2025;5(2):506–12. doi: 10.55606/nusantara.v5i2.5205.
Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of sample size in health studies [Internet]. Geneva: World Health Organization; 1990. Available from: https://digitallibrary.un.org/record/49698?ln=en.
Jendrike N, Baumstark A, Pleus S, Mende J, Haug C, Freckmann G. Assessment of system accuracy, intermediate measurement precision, and measurement repeatability of a blood glucose monitoring system based on ISO 15197. J Diabetes Sci Technol. 2019 Mar;13(2):235–41. doi: 10.1177/1932296818821105.
Wu N, Xia J, Chen S, Yu C, Xu Y, Xu C, et al. Serum uric acid and risk of incident chronic kidney disease: a national cohort study and updated meta-analysis. Nutr Metab (Lond). 2021 Oct 19;18(1):94. doi: 10.1186/s12986-021-00618-4.
Kannuthurai V, Gaffo A. Management of patients with gout and kidney disease: a review of available therapies and common missteps. Kidney360. 2023 Sep 1;4(9):e1332–40. doi: 10.34067/KID.0000000000000221.
Hisatome I, Li P, Miake J, Taufiq F, Mahati E, Maharani N, et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular disease ― Japanese guideline on the management of asymptomatic hyperuricemia ―. Circ J. 2021 Jan 25;85(2):130–8. doi: 10.1253/circj.CJ-20-0406.
Usman Sagheer M, Dinesh K. Kalra MF. National Lipid Association [Internet]. [cited 2026 Apr 26]. Lipid luminations: lipid management in chronic kidney disease | national lipid association online. Available from: https://www.lipid.org/lipid-spin/spring-2024/lipid-luminationslipid- management-chronic-kidney-disease.
Suh SH, Kim SW. Dyslipidemia in patients with chronic kidney disease: an updated overview. Diabetes Metab J. 2023 Sep;47(5):612–29. doi: 10.4093/dmj.2023.0067.
Afshinnia F, Pennathur S. Lipids and cardiovascular risk with CKD. Clin J Am Soc Nephrol. 2020 Jan;15(1):5–7. doi: 10.2215/CJN.13531119.
Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and progression of chronic kidney disease: a review from physiology and pathogenesis to the role of urate-lowering therapy. Diagnostics (Basel). 2021 Sep 13;11(9):1674. doi: 10.3390/diagnostics11091674.
Pluddemann A, Thompson M, Price CP, Wolstenholme J, Heneghan C. Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update. Br J Gen Pract. 2012 Mar 1;62(596):e224–6. doi: 10.3399/bjgp12X630241.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Muhammad Fikri Dzakwan, Diana Dinali, Steve Geraldo Bustam, Shirly Gunawan, Yohanes Firmansyah

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.






